Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 2/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 3/20 | 0.43 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.43 |
| ▸ | ABAT | P80404 | 2/20 | 0.42 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7648199 | 0.98 | IDO1 (0.48) | IDO1MEN1KMT2AESR1ESR2 | |
| SCHEMBL11392894 | 0.90 | CA2 (0.39) | IDO1MEN1KMT2ACA2 | |
| Phenol SCHEMBL28213971 | 0.85 | LMNA (0.48) | IDO1MEN1KMT2ACA2 | |
| SCHEMBL18544386 | 0.84 | LTA4H (0.39) | IDO1CA2 | |
| SCHEMBL11320245 | 0.83 | IDO1 (0.41) | IDO1CA2 | |
| SCHEMBL11316154 | 0.83 | ESR1 (0.42) | KMT2AESR1ESR2CA2 | |
| SCHEMBL6237288 | 0.80 | ESR1 (0.52) | KMT2AESR1ESR2CA2 | |
| SCHEMBL27652653 | 0.80 | CYP1A2 (0.42) | MEN1KMT2AESR1ESR2 | |
| SCHEMBL17321077 | 0.79 | TRPA1 (0.39) | IDO1CA2 | |
| SCHEMBL9881633 | 0.79 | CA2 (0.32) | CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 153 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5500668-A | INK JET PRINTING | XEROX CORPORATION (US) | 1996-03-19 | — | — | US | claimed |
| EP-0560269-B1 | Substituted pyrrolidine derivatives as HIV protease inhibitors | BIO MEGA BOEHRINGER INGELHEIM (CA) | 1995-05-31 | — | — | EP | claimed |
| EP-0560268-B1 | Substituted pipecolinic acid derivatives as HIV protease inhibitors | BIO MEGA BOEHRINGER INGELHEIM (CA) | 1995-01-04 | — | — | EP | claimed |
| WO-1993018003-A1 | SUBSTITUED PIPECOLINIC ACID DERIVATIVES AS HIV PROTEASE INHIBITORS | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1993-09-16 | — | — | WO | claimed |
| EP-0560269-A1 | Substituted pyrrolidine derivatives as HIV protease inhibitors | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1993-09-15 | — | — | EP | claimed |
| EP-0560268-A1 | Substituted pipecolinic acid derivatives as HIV protease inhibitors | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1993-09-15 | — | — | EP | claimed |
| EP-0062717-B1 | A PROCESS FOR THE MANUFACTURE OF AROMATIC CYANIDES | A.H. Marks & Co. Limited (GB) | 1985-07-03 | — | — | EP | claimed |
| EP-0062717-A1 | A process for the manufacture of aromatic cyanides | A.H. Marks & Co. Limited (GB) | 1982-10-20 | — | — | EP | claimed |
| WO-2024133815-A1 | ANTIBODY-DRUG CONJUGATES WITH MASKED PBD DIMERS | SYNAFFIX B.V. (NL) | 2024-06-27 | — | — | WO | disclosed |
| EP-4389152-A1 | CONJUGATES OF PBD PRODRUGS | Synaffix B.V. (NL) | 2024-06-26 | — | — | EP | disclosed |
| US-20230346752-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION | 2023-11-02 | — | — | US | disclosed |
| US-20230346752-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION | 2023-11-02 | — | — | US | disclosed |
| US-20230293497-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230293497-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION (US) | 2023-09-21 | — | — | US | disclosed |
| EP-0178911-A2 | Composition containing a penem or carbapenem antibiotic | SANKYO COMPANY LIMITED (JP) | 1986-04-23 | — | — | EP | disclosed |
| EP-0062717-B1 | A PROCESS FOR THE MANUFACTURE OF AROMATIC CYANIDES | A.H. Marks & Co. Limited (GB) | 1985-07-03 | — | — | EP | disclosed |
| US-4378319-A | Process for the manufacture of aromatic cyanides | A. H. MARKS & CO., LIMITED (GB) | 1983-03-29 | — | — | US | disclosed |
| US-4378319-A | Process for the manufacture of aromatic cyanides | A. H. MARKS & CO., LIMITED (GB) | 1983-03-29 | — | — | US | disclosed |
| EP-0062717-A1 | A process for the manufacture of aromatic cyanides | A.H. Marks & Co. Limited (GB) | 1982-10-20 | — | — | EP | disclosed |
| EP-0062717-A1 | A process for the manufacture of aromatic cyanides | A.H. Marks & Co. Limited (GB) | 1982-10-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230293497-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | IDO1 3758/4885MEN1 367/4885KMT2A 2431/4885 |
| US-20230346752-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | IDO1 3758/4885MEN1 367/4885KMT2A 2431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.